Plymouth Meeting, PA – September 30, 2015: CRF Health, the leading global provider of eCOA solutions for the life sciences industry, today introduced an eCOA solution to eliminate data collection challenges and reduce patient burden in Chronic Obstructive Pulmonary Disease (COPD) trials. Patient-tested, CRF Health's complete TrialMax® eCOA solution provides electronic versions of the St. George's Hospital Respiratory Questionnaire for COPD patients (SGRQ-C) and the COPD Assessment Test (CAT) which have been demonstrated to be easy-to-use and provide comparable data to their paper originals. The result is an eCOA solution that brings together activity monitor data, patient-reported outcome and symptom data to deliver the clearest overview of a patient's condition.
The SGRQ-C and CAT instruments have undergone electronic equivalence testing on CRF Health's TrialMax Slate® site-based eCOA solution to demonstrate that the questionnaires are interpreted and responded to in the same way as their paper counterparts. For sponsors, CRF Health's validation testing means they can utilize the resulting equivalency report as part of their overall regulatory submission, removing the time and expense required to conduct a standalone equivalence study themselves.
"Our experience of collecting clinical outcomes assessment data in over 30 COPD trials has demonstrated the need for tools that make the process as burden-free and simple for patients as possible. CRF Health's COPD solution allows investigators to concentrate their attention on what matters most, their patients, by making it possible to leverage key COPD instruments and easily monitor exacerbations", comments Paul O'Donohoe, Director of Health Outcomes at CRF Health. "We are now pleased to be able to share the evidence of our equivalency testing with customers which will simplify the process of their regulatory submissions."
With a patient population struggling with lowered energy levels, reduced compliance in COPD trials can become a prevalent issue due to the large burden placed on patients to report their symptoms and complete patient reported outcomes. The TrialMax solution utilizes a patient-friendly electronic diary to monitor exacerbations and minimize the burden on sick patients, while achieving a more complete data set through better compliance.
For further information on CRF Health, please visit www.crfhealth.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.